NCT02598596 - Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect | Biotech Hunter

Enrollment

132

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

April 13, 2020

Study Completion Date

April 27, 2020

Conditions

Gout

Interventions

BIOLOGICAL

Pegloticase

Pegloticase, IV

DRUG

Azathioprine

Azathioprine (1.25 mg/kg, followed by 2.5 mg/kg) oral, daily

Trial Locations (11)

10467

Montefiore Medical Center, The Bronx

14127

Buffalo Rheumatology and Medicine, Orchard Park

16635

Altoona Center for Clinical Research, Duncansville

20902

The Center for Rheumatology and Bone Research, Wheaton

29118

ACME Research, LLC, Orangeburg

35294

University of Alabama at Birminingham, Birmingham

35801

Rheumatology Associates of North Alabama, Huntsville

44195

Cleveland Clinic, Cleveland

48202

Henry Ford Health System, Detroit

55121

Saint Paul Rheumatology, Eagan

01609

Clinical Pharmacology Study Group, Worcester

All Listed Sponsors

collaborator

IND 2 Results LLC

INDUSTRY

lead

Ampel BioSolutions, LLC

INDUSTRY